미용 주사제 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Aesthetic Injectable Market Summary

The global aesthetic injectable market size was estimated at USD 11.1 billion in 2025 and is projected to reach USD 24.1 billion by 2033, growing at a CAGR of 10.0% from 2026 to 2033. The rising demand for minimally invasive aesthetic procedures is significantly driving the growth of the aesthetic injectables industry.

Consumers are increasingly seeking subtle, non-surgical enhancements with minimal downtime, boosting the adoption of products such as botulinum toxins, dermal fillers, and biostimulatory injectables. These treatments effectively address concerns such as wrinkles, volume loss, and skin quality, delivering natural-looking results from immediate to gradual effects. This shift has expanded the consumer base to include both corrective and preventive users. In June 2024, an article published in the European Journal of Plastic Surgery analyzed 511 websites across Germany, Austria, and Switzerland, highlighting the strong presence and demand for non-surgical aesthetic procedures, reinforcing their growing role in modern clinical practice.

The social acceptance of injectable treatments has also expanded the customer base beyond traditional segments. Younger consumers view dermal fillers as a proactive approach to aging, while older individuals appreciate the restoration of youthful features without going under the knife. With influencers and professionals normalizing these treatments, demand continues to grow in both urban and emerging markets. Patients value the ability to personalize results progressively and affordably. The rise of curated aesthetic journeys, guided by skilled practitioners, reinforces confidence in these procedures. In January 2024, Allergan Aesthetics revealed that its Alle loyalty rewards program achieved a 92% satisfaction rate in a consumer survey. Serving over six million members, Alle offers benefits such as cost savings, points on non-Alle treatments, and exclusive rewards for loyal users, making it a trusted resource for consumers and providers alike.

Global Aesthetic Injectable Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global aesthetic injectable market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Collagen and PMMA Microspheres
• Hyaluronic Acid
  • Monophasic
  • Biphasic
• Calcium Hydroxylapatite (CaHA)
• PLLA
• PCL
• PN/PDRN
• Botulinum Toxin (Botox)
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Wrinkle Correction
• Lip Augmentation
• Facial Contouring
• Scar Treatment
• Volume Loss Restoration
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• MedSpas
• Aesthetic Surgery Centers
• Hospitals
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Russia
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • Singapore
  • Malaysia
  • Taiwan
  • India
  • Vietnam
  • Philippines
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Aesthetic Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Aesthetic Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Aesthetic Injectable Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Aesthetic Injectable Market: Product Movement Analysis
• 4.3. Aesthetic Injectable Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Collagen and PMMA Microspheres
  • 4.5.1. Collagen and PMMA Microspheres Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Hyaluronic Acid
  • 4.6.1. Hyaluronic Acid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Monophasic
    • 4.6.2.1. Monophasic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Biphasic
    • 4.6.3.1. Biphasic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Calcium Hydroxylapatite (CaHA)
  • 4.7.1. Calcium Hydroxylapatite (CaHA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. PLLA
  • 4.8.1. PLLA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. PCL
  • 4.9.1. PCL Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. PN/PDRN
  • 4.10.1. PN/PDRN Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Botulinum Toxin (Botox)
  • 4.11.1. Botulinum Toxin (Botox) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Aesthetic Injectable Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Aesthetic Injectable Market: Application Movement Analysis
• 5.3. Aesthetic Injectable Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Wrinkle Correction
  • 5.5.1. Wrinkle Correction Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Lip Augmentation
  • 5.6.1. Lip Augmentation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Facial Contouring
  • 5.7.1. Facial Contouring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Scar Treatment
  • 5.8.1. Scar Treatment Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Volume Loss Restoration
  • 5.9.1. Volume Loss Restoration Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Aesthetic Injectable Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Aesthetic Injectable Market: End Use Movement Analysis
• 6.3. Aesthetic Injectable Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. MedSpas
  • 6.5.1. MedSpas Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Aesthetic Surgery Centers
  • 6.7.1. Aesthetic Surgery Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Aesthetic Injectable Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Aesthetic Injectable Market Movement Analysis
• 7.3. Aesthetic Injectable Market: Regional Estimates & Trend Analysis by Product & Source
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.10. Russia
    • 7.6.10.1. Key Country Dynamics
    • 7.6.10.2. Competitive Scenario
    • 7.6.10.3. Regulatory Framework
    • 7.6.10.4. Reimbursement scenario
    • 7.6.10.5. Russia Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.8. Singapore
    • 7.7.8.1. Key Country Dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory Framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Singapore Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.9. Malaysia
    • 7.7.9.1. Key Country Dynamics
    • 7.7.9.2. Competitive Scenario
    • 7.7.9.3. Regulatory Framework
    • 7.7.9.4. Reimbursement scenario
    • 7.7.9.5. Malaysia Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.10. Taiwan
    • 7.7.10.1. Key Country Dynamics
    • 7.7.10.2. Competitive Scenario
    • 7.7.10.3. Regulatory Framework
    • 7.7.10.4. Reimbursement scenario
    • 7.7.10.5. Taiwan Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.11. Vietnam
    • 7.7.11.1. Key Country Dynamics
    • 7.7.11.2. Competitive Scenario
    • 7.7.11.3. Regulatory Framework
    • 7.7.11.4. Reimbursement scenario
    • 7.7.11.5. Vietnam Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.12. Philippines
    • 7.7.12.1. Key Country Dynamics
    • 7.7.12.2. Competitive Scenario
    • 7.7.12.3. Regulatory Framework
    • 7.7.12.4. Reimbursement scenario
    • 7.7.12.5. Philippines Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Aesthetic Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. AbbVie Inc.
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Galderma
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Merz GmbH and Co. KGaA
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Sinclair
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Medytox
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Prollenium Medical Technologies
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Tiger Aesthetics Medical (Suneva Medical, Inc.)
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. HUGEL, Inc.
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Ipsen Pharma
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Teoxane
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives